Gene therapy using Aβ variants for amyloid reduction.

Abstract excerpt

Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be achieved by peptide inhibitors, translation of these strategies has been thwarted by two key obstacles: rapid proteolytic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer Disease
• Share to Amyloid beta-Peptides